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Ret is essential to mediate GDNF’s neuroprotective and
neuroregenerative effect in a Parkinson disease
mouse model
Anja Drinkut1,2, Karsten Tillack3,7,8, Durga P Meka3,7, Jorg B Schulz*,1,2,4,9, Sebastian Kügler1,5,9 and Edgar R Kramer*,3,6,9
Glial cell line-derived neurotrophic factor (GDNF) is a potent survival and regeneration-promoting factor for dopaminergic neurons
in cell and animal models of Parkinson disease (PD). GDNF is currently tested in clinical trials on PD patients with so far
inconclusive results. The receptor tyrosine kinase Ret is the canonical GDNF receptor, but several alternative GDNF receptors have
been proposed, raising the question of which signaling receptor mediates here the beneficial GDNF effects. To address this
question we overexpressed GDNF in the striatum of mice deficient for Ret in dopaminergic neurons and subsequently challenged
these mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Strikingly, in this established PD mouse model, the absence
of Ret completely abolished GDNF’s neuroprotective and regenerative effect on the midbrain dopaminergic system. This
establishes Ret signaling as absolutely required for GDNF’s effects to prevent and compensate dopaminergic system
degeneration and suggests Ret activation as the primary target of GDNF therapy in PD.
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Glial cell line-derived neurotrophic factor (GDNF) is the
founding member of the four ligands in the GDNF family,
which belong to the transforming growth factor-β superfamily.1
GDNF was characterized as a potent survival factor for many
neurons in culture such as dopaminergic, motor, sympathetic,
parasympathetic, sensory and enteric neurons.1,2 In addition,
in dopaminergic neuron cultures GDNF stimulates neuronal
differentiation, neurite outgrowth, synapse formation and
dopamine release.1,2
As degeneration of midbrain dopaminergic neurons in the
substantia nigra pars compacta (SNpc) represents a major
hallmark of Parkinson disease (PD), the most common
neurodegenerative movement disorder, GDNF has raised
considerable interest as a therapeutic molecule for the
treatment of PD.3–5 PD affects 42% of individuals over the
age of 60 years, but no curative treatment is available to date,
mainly due to a lack of understanding disease etiology.6–8
Preclinical studies in the established 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine
(6-OHDA) rodent and primate models of PD demonstrated a
substantial neuroprotection and regeneration effect by striatal
provided GDNF or its close relative neurturin.3,4,9 However,
clinical phase II trials on PD patients using GDNF or neurturin
did so far not convincingly recapitulate their beneficial effects
on the dopaminergic system in humans most likely due to
technical problems and the selection of advanced PD
patients.10–13
GDNF signaling is highly complex as this neurotrophic
factor can bind to a variety of receptors, thus being able to
induce pleiotropic effects. GDNF efficiently binds to the GPI-
linkedGDNF family receptor α1 (GFRα1).1,2 It has been shown
that the GDNF/GFRα1 complex can activate not only the
canonical GDNF receptor Ret, a receptor tyrosine kinase
which signals through the sarcoma protein (Src)/rat sarcoma
(Ras)/mitogen-activated protein kinase (MAPK), phosphati-
dylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt, NF-κB
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(nuclear factor 'kappa-light-chain-enhancer' of activated B
cells), JNK (c-Jun N-terminal kinases) and PLCγ (phospholi-
pase γ) pathway, but also with other signaling inducing
receptors.1,2,4,5,13 So far, at least four alternative GDNF
receptors have been described which are all expressed in
midbrain dopaminergic neurons, NCAM,14,15 the integrins αV
and βI,14,16 syndecan 317 and N-cadherin.18 Interestingly, Ret
is not essential during pre- and postnatal development of the
mouse dopaminergic system,19–23 but specifically required for
the maintenance of SNpc dopaminergic neurons and their
striatal innervation in aged mice.23–25 In contrast, GDNF
seems most likely under physiological conditions to be
dispensable during development and maintenance of mid-
brain dopaminergic neurons in mice, although conflicting
results exist.26–28 Thus, Ret might be activated by a GDNF-
independent mechanism to stimulate SNpc dopaminergic
neuron survival. In addition, the in vivo function of the
alternative GDNF receptors in the dopaminergic system under
physiological and pathophysiological conditions, like PD, and
their dependence on GDNF has not yet been addressed in
detail. This raised the important question which GDNF
receptor might be required to mediate GDNF’s reported
neuroprotective and regenerative effect in the dopaminergic
system in PD animal models and potentially in PD patients.5,29
Previously, we showed in dopaminergic neuron-specific Ret
knockout mice that Ret receptor loss does not result in a higher
vulnerability of midbrain dopaminergic neurons against MPTP
but to less resprouting of left over dopaminergic neuron axons
in the striatum after MPTP intoxication.30 In adult mice
endogenous GDNF levels are rather low.26,31 Therefore, we
could not rule out in that study the possibility, that higher levels
of GDNF—as also used in the clinical GDNF trials in PD
patients—might have neuroprotective and regenerating
effects even in the absence of the Ret receptor. Here we
addressed now this question by viral overexpression of GDNF
in MPTP-treated mice lacking expression of Ret again
specifically in dopaminergic neurons.23,30 We found that in
the absence of Ret in dopaminergic neurons even a
substantial overexpression of GDNF in the striatum does not
have a neuroprotective and regenerative effect. Thus, despite
the expression of alternative GDNF receptors on midbrain
dopaminergic neurons, the presence of the canonical GDNF
receptor Ret seems to be mandatory for mediating GDNF’s
beneficial survival and axonal resprouting effect in these
neurons.
Results
To investigate the Ret receptor function in mediating the
neuroprotective and neuroregenerative effects of GDNF we
generated mice with a disrupted Ret gene specifically in
dopaminergic neurons (DAT-Retlx/lx)23 by crossing mice
carrying the floxed allele of Ret (Retlx/lx)32 with dopamine
transporter (DAT) promoter-driven Cre mice (DAT-Cre).33 We
overexpressedGDNF in thesemice by stereotactic injection of
a recombinant adeno-associated virus serotype 5 (AAV5)
encoding the mouse GDNF cDNAunder the control of the glial
fibrillary acidic protein (GFAP) promoter (AAV5-GDNF) uni-
laterally in the striatum of the left mouse brain hemisphere
(Figure 1g and h).34 The contralateral hemisphere of the same
animal served as an internal control as we found that this
expression mode restricted the delivery of GDNF to only the
vector-injected hemisphere (Figure 1g).34 Besides injecting a
control virus encoding the enhanced green fluorescent protein
under the GFAP promoter (AAV5-EGFP) in some mice
confirming astrocyte-specific transgene expression, we also
unilaterally sham-injected some mice (Figure 1a–f). Two
weeks after injection of AAV5-GDNF we determined by
immunohistochemical (IHC) and enzyme-linked immunoab-
sorbent assay (ELISA) the striatal GDNF levels to be
87 961 pg/mg tissue and the nigral GDNF levels of 1097 pg/
mg tissue, whereas in AAV5-EGFP-injected animals striatal
GDNF levels were 40 and 18 pg/mg tissues in the nigra. Thus,
we achieved with the AAV5-GDNF vector an around 2200-fold
and 61-fold overexpression of GDNF in the striatum and in the
SNpc compared with AAV5-EGFP-injected mice, respectively
(Figure 1g; Supplementary Figure 1). GDNF is spreading over
the whole brain hemisphere sterotactically injected including
the striatum and cortical regions (Supplementary Figure 1).
The leakage of GDNF to the contralateral side is only threefold
in the striatum and 12-fold in the substantia nigra (Figure 1g).
In our paradigm 1 week after virus injection the mice were
challenged with a systemic subchronic MPTP treatment
leading to 40–60% of dopaminergic system lesion or were
treated with saline (NaCl) as a control (Figure 1h).30 The
nigrostriatal dopaminergic system of thesemice was analyzed
2 weeks later to monitor the neuroprotective effect of GDNF
and three months after the MPTP treatment to investigate the
neuroregenerative potential of GDNF (Figure 1h).30
First, we stereologically quantified the number of tyrosine
hydroxylase (TH)-positive dopaminergic neurons of the SNpc
in the mouse brains 2 weeks after MPTP treatment. In all three
genotypes (DAT-Cre, Retlx/lx and DAT-Retlx/lx) MPTP reduced
the number of dopaminergic neurons by 46% (3000–4000
cells per brain half) compared with saline (NaCl)-treated mice
(Figure 2a). Injection of AAV5-EGFP did not reduce MPTP-
induced cell death in any genotype (Figure 2a). As expected,
GDNF was neuroprotective in the AAV5-GDNF-treated brain
hemisphere of control mice (DAT-Cre and Retlx/lx) and MPTP
induced o20% loss of dopaminergic neurons (Figure 2a). In
contrast, GDNF expression conferred no neuroprotective
effect against MPTP in Ret-deficient mice (DAT-Retlx/lx). Thus,
in the absence of Ret, even substantial amounts of GDNF did
not protect dopaminergic neurons from MPTP toxicity. The
same cell numbers were also observed in mice analyzed
3 months after MPTP treatment confirming the long-term
neuroprotective effect of GDNF/Ret on dopaminergic neurons
and also the general lack of dopaminergic cell regeneration
after MPTP treatment independent of GDNF overexpression
or not (Figure 2b). We did not observe a significant motor
impairment in the MPTP-treated mice compared with the
NaCl-treated mice using the open field, Rotarod and tight rope
test, and could therefore not followGDNF’s beneficial effect on
the behavior (data not shown). This is most likely due too50%
dopaminergic cell loss with the MPTP treatment (Figure 2).
Next, we investigated if GDNF’s dopaminergic innervation
protective function after MPTP treatment depends on the Ret
receptor. Therefore, we assessed TH- and DAT- positive
dopaminergic fibers in the striatum of the three genotypes
2 weeks and 3 months after MPTP intoxication (Figure 3;
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Supplementary Figures 2–5). Two weeks after MPTP treat-
ment the striatal dopaminergic innervation was reduced by
almost 50% in all three genotypes compared with NaCl-
treated mice (Figure 3a). Injection of AAV5-EGFP had no
influence on the MPTP-induced striatal dopaminergic axon
loss (Figure 3a). Although the AAV5-GDNF-treated brain
hemisphere of control mice treated with MPTP showed almost
no degeneration of the striatal dopaminergic innervation, no
protection was detectable in DAT-Retlx/lx mice (Figure 3b).
Besides quantifying the 3,3-Diaminobenzidin (DAB) staining
of the TH-positive fibers in the striatum (Figure 3), which does
not allow to distinguish between alterations in TH protein and
alterations in the amount of TH-positive fibers, we also
performed a fluorescent TH staining and quantified precisely
the relative density of dopaminergic fibers in the dorsal and
ventral striatum using TH andDATasmarkers (Supplementary
Figures 2–5). These experiments support the DAB data.
To investigate the extent to which the residual dopaminergic
fibers in the striatum remained functional, we quantified
the total concentration of dopamine and its metabolites
3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
acid (HVA) in the striatum two weeks after MPTP treatment
(Figure 4a; Supplementary Figure 4). Consistent with the
dopaminergic fiber density also dopamine, DOPAC and HVA
levels were only protected in the GDNF expressing hemi-
sphere of DAT-Cre and Retlx/lx mice but not in DAT-Retlx/lx mice
(Figure 4a). This shows that the protective function of
exogenous GDNF on dopaminergic cell bodies and axons in
the MPTPmodel depends on the presence of the Ret receptor
in dopaminergic neurons.
Finally, we assessed GDNFs regeneration function at
3 months after MPTP in the three genotypes by quantifying
TH- and DAT-positive fibers in the striatum (Figure 3c;
Supplementary Figures 5 and 6). As observed previously,30
resprouting of the residual dopaminergic fibers after partial
denervation by MPTP strictly depends on the presence of the
Ret receptor and is already induced by endogenous levels of
GDNF (about 0.04 ng/mg tissue; Figure 3c). Thus, substantial
regeneration of dopaminergic fibers to 70–80% of saline
injected control mice was detected in MPTP-treated DAT-Cre
and Retlx/lx mice in the non-AAV-injected control brain site as
well as in the AAV5-EGFP injected hemispheres, but not in
Ret-deficient mice (Figure 3c). A significant additional
regenerating effect of up to 90–100% of NaCl-treated control
Figure 1 Tools and paradigm to address Ret function in mediating GDNF neuroprotective and regenerative effect in the MPTP mouse model of PD. (a–f) Coronal striatum
sections are shown for the three mouse genotypes (DAT-Cre, Retlx/lx and DAT-Retlx/lx) which were transduced with an adeno-associated virus of the serotype 5 encoding EGFP
under the GFAP promoter to target astrocytes (AAV5-EGFP). (a–c) EGFP expression in the striatum of the left brain hemisphere at low resolution (scale bar, 500 μm). (d–f)
EGFP expression in green co-localizes in astrocytes immunohistochemically stained in red with antibodies against GFAP (scale bar, 20 μm). (g) Schema shows absolute values
of GDNF measured by ELISA in pg/mg tissue (red numbers) and fold of GDNF overexpression (blue numbers) of AAV5-GDNF injected mice in comparison to AAV5-EGFP
injected wild-type animals with 40 pg GDNF/mg tissue in the striatum and 18 pg GDNF/mg tissue in the nigra. Only 1.3% of the GDNF expressed in the infected striatum is
retrograde transported into the ipsilateral substantia nigra (green number). (h) Schema illustrating the experimental paradigm used
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mice was detectable in the ipsilateral of AAV5-GDNF injected
and MPTP-treated DAT-Cre and Retlx/lx mice (Figure 3c). But
even after high- and long-term overexpression of GDNF no
regeneration of dopaminergic fibers was detectable in the
striatum of DAT-Retlx/lx mice (Figure 3c). The quantification of
fluorescently labeled fibers reveals besides GDNF’s neuro-
protective effect also the significant resprouting of TH-positive
fibers in the two control groups between 2weeks and 3months
from 18 to 37% on the AAV5-GFP injected side of MPTP
treated mice and 43 to 68% on the AAV5-GDNF injected side
of MPTP treated mice compared with sham-injected mice
(Supplementary Figures 2 and 4). We conclude that resprout-
ing of dopaminergic axons after MPTP intoxication even in the
presence of exogenous GDNF strictly depends on the
presence of the Ret receptor. We also determined striatal
levels of dopamine and its metabolites DOPAC and HVA by
HPLC to rule out that GDNF might not influence the
physiologically important neurotransmitter levels even in the
absence of dopaminergic fiber regeneration in the Ret-
deficient mice (Figure 4b; Supplementary Figure 4). However,
in contrast to control mice where dopamine levels increased
corresponding to the degree of regeneration no recovery of the
dopamine levels took place in Ret-deficient mice demonstrat-
ing that also no functional recovery of the dopaminergic
system is possible in the absence of Ret (Figure 4b).
To find out if our AAV5 vectors have a general effect on the
brain physiology we also analyzed the glia response in our
mice (Supplementary Figure 7). Although we did not find
alterations in the number of microglia quantified with anti-
bodies against ionized binding calcium adapter molecule
(Iba)-1 in the SN and striatum, they led to a low, but persistent,
increase in GFAP positive astrocyctes in the striatum 3months
after the MPTP treatment in addition to the previously
described transient increase of astrocytes at two weeks after
the MPTP treatment30 (Supplementary Figure 7). This mild
gliosis seem not to be influenced by GDNF expression and
seems also not to interfere with the observed beneficial effect
of GDNF/Ret signaling on dopaminergic neuron regeneration.
Discussion
We described in Kowsky et al.30 already that the absence of
Ret does not decreaseMPTP vulnerability leading to the same
MPTP induced cell loss but prevents subsequent regeneration
of dopaminergic fibers most likely mediated by endogenous
GDNF. Here, in this manuscript, we overexpress now in
addition GDNF before the MPTP treatment (Figure 1). This
allows us to show in Ret expressing mice 2 weeks after MPTP
treatment the neuroprotective effect of GDNF on the dopami-
nergic cell bodies and fibers in the striatum and additionally
3 months after MPTP treatment a more pronounced stimula-
tory effect of GDNF on regenerating dopaminergic fibers in the
striatum (Figure 3; Supplementary Figures 2–5). Thus,
indeed, we could show different effects of GDNF/Ret signaling
on the midbrain dopaminergic cell body and the striatal
dopaminergic innervation. The dopaminergic cell bodies
require Ret for exogenous GDNF-induced protection from
MPTP toxicity, although enhanced GDNF/Ret signaling
cannot induce cell proliferation (Figure 2). In addition, Ret is
required in the dopaminergic axons to mediate there
exogenous GDNF’s protective and regenerative effect
(Figure 3; Supplementary Figures 2–5). This exogenous
GDNF protects and also allows to partially recover the
dopamine levels in the presence of Ret (Figure 4) suggesting
for exogenous GDNF not only a beneficial effect on the fiber
histology but also on the physiology. As the absence of Ret
abolished already completely GDNF’s neuroprotective func-
tion there was no need to apply GDNFafter the MPTP induced
degeneration to investigate only GDNF’s regenerative func-
tion. Although the MPTP model of PD does not mimic all
aspects of idiopathic PD,35,36 it is a robust lesion model that
allowed us to assess the requirement of Ret-mediated GDNF
signaling. In our previouswork we already established that Ret
loss does not alter MPTP metabolism.30
Our result, that GDNF can provide its neuroprotective and
neuroregenerative function on midbrain dopaminergic neu-
rons only in the presence of the receptor tyrosine kinase Ret,
has practical implications for therapeutic strategies to treat PD
with GDNF and neurturin.3,7,11,12,13 It suggests that the main
Figure 2 Stereological quantification of nigral dopaminergic neurons. Numbers of TH and Nissl-positive nigral neurons are shown for the three genotypes (Dat-Cre, Retlx/lx
and DAT-Retlx/lx) 2 weeks post MPTP treatment (a) and 3 months after MPTP treatment (b) and control mice which instead received saline (NaCl) (a and b). For each mouse the
numbers on the side with mock injection (inj), AAV5-EGFP injection (EGFP) or AAV5-GDNF (GDNF) and on the non-injected contralateral side (con) are shown (n= 6 animals
per group)
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goal of clinical trials using GDNF and related substances
should be to activate the Ret receptor. In our experiments even
striatal GDNF levels 2000-fold above endogenous levels for
43 months were not sufficient to reveal any Ret-independent
neuroprotective or regenerative effect of GDNF in the MPTP
mouse model of PD. As the Ret receptor is only expressed in
the dopaminergic system in dopaminergic neurons of the
midbrain and GDNF expression was not able to suppress the
mild but long-term gliosis in the SNpc, this supports the idea
that GDNF stimulates directly intrinsic survival and resprouting
pathways in dopaminergic neurons and additional effect on
glia cells and other neurons seem less important. Thus, GDNF
can only function efficiently when enough dopaminergic
neurons are still around which express the Ret receptor.5,29
Late stage PD patients with too few dopaminergic cells and
strongly reduced striatal dopaminergic innervation will most
likely not be able to respond efficiently to GDNFand should be
excluded from the clinical GDNF trials. A PD therapy based on
stimulating Ret signaling in dopaminergic neurons of the SN
should be most effective in the early phase of the disease
when there are still many dopaminergic neurons present on
which Ret can mediate survival of dopaminergic neurons,
protection from toxic insults, and resprouting of fibers
in the striatum.3,7,11,12,13 Neurturin binds with high affinity on
GFRα2,1 which is expressed in the ventral midbrain but not on
midbrain dopaminergic neurons.37–39 This suggests that
neurturin might stimulate Ret on dopaminergic neurons by
low affinity binding to GFRα1 or supports dopaminergic
neurons in a non-cell-autonomous manner.39
Interestingly, endogenous GDNF has been shown to be
expressed in the adult striatum only in fast spiking,
parvalbumin-positive GABAergic interneurons—representing
0.7% of all striatal neurons—and to a lower extent in some
somatostatinergic and cholinergic interneurons, but not in
medium spiny neurons.13,31,40 As GDNF cannot pass the
blood–brain barrier (BBB), exogenous GDNF must be
provided for the clinical trials by specific routes. GDNF protein
can be intrastriatal or intranasal infused, modified or packaged
GDNF that can pass the BBB might be supplied systemically,
GDNF encoding DNA constructs might be provided by viral
vectors, or GDNF expressing cells might be transplanted into
the striatum.3,7,11,12,13,41 Previously we compared astrocytic
(human GFAP promoter) and neuronal (human synapsin 1
promoter) expression levels of GDNF with the AAV5 serotype
vector and found similar GDNF expression levels in the
injected side but less spreading to the contralateral side using
the GFAP promoter.34 It has already been previously shown
that AAV serotype 5 allows wide spreading of the virus in the
striatum and efficient targeting of astrocytes.34,42 The GFAP
promoter led to high- and long-term GDNF expression in
astrocytes without adverse effects as also shown previously in
adeno- and lentivirus vectors.34,43,44 This is in contrast to high
expression of GDNF in striatal and nigral neurons which can
lead to negative side effects, such as downregulation of TH
protein levels.45–48 If in clinical trials the amount of bioactive
GDNF in the striatum is limiting, the here used AAV5-GDNF
serotype 5 vector with the GFAP promoter seems to be an
efficient and safe alternative to provide GDNF.34 Further
experiments are needed to clarify if the mild striatal gliosis
Figure 3 Quantification of striatal dopaminergic fiber density. TH immunoreactivity of striatal tissue sections is shown in a for DAT-Cre mice (upper panel), Retlx/lx mice (middle
panel) and DAT-Retlx/lx mice (lower panel) at 2 weeks after MPTP treatment (first two columns) and 3 months after MPTP treatment (last two columns), for the injected
hemispheres (inj., columns 1 and 3) and the contralateral hemispheres (con, columns 2 and 4). The quantification of striatal TH fiber density is presented in (b) for 2 weeks, and in
c for 3 months after MPTP application. Scale bar, 40 μm in (a) (n= 6 animals per group)
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found in our mice is also observed in humans and if this results
in negative side effects.
Previous work has already shown that GDNF’s neuropro-
tective function requires not only Ras-MAPK activation but
also PI3K-Akt signaling.5,30,49–51 It is also well established that
the Ret receptor it essential for maintaining aged SNpc
dopaminergic neurons and seems to crosstalk for this
maintenance function with proteins such as the chaperon
DJ-1, PINK-1 (PTEN-induced putative kinase 1) and parkin,
an E3 ubiquitin-protein ligase, for which mutated forms were
found to lead to PD.5,24,25,29,52,53 Ret and DJ-1 (deglycase)
trigger dopaminergic cell survival in mice by activating
together the Ras/MAPK pathway.24 Ret crosstalks with
PINK-1 and parkin to ensure mitochondrial morphological
and physiological integrity in dopaminergic neurons.25,52,53
Ret and parkin are not only important for survival of
aged dopaminergic cell body in the SNpc but also for the
maintenance of the striatal dopaminergic innervation.5,25,29,53
Therefore, we suspect that these signaling events down-
stream of the Ret receptor play also an important role in
mediating GDNF’s neuroprotective and regenerative function
in the dopaminergic system.
Although we have shown here the requirement for Ret for
mediating GDNF’s neuroprotective and regenerative effect in
midbrain dopaminergic neurons, this does not rule out an
additional function for alternative GDNF receptors in this
context and also for mediating survival during development
and maintenance of these neurons. The recent finding, that
GDNF might be dispensable for the development and
maintenance of the dopaminergic system in mice26,27,28
supports the idea, that alternative GDNF receptors might
even function without the need to bind GDNF as important
signaling recognition or cell adhesion molecules in dopami-
nergic neurons. Further studies are needed to clarify the
physiological function of alternative GDNF receptors and
GDNF itself in mice and man.
Small molecules that specifically activate Ret and can cross
the BBB would be ideal and seem to be an achievable goal as
small non-peptidyl quinol based GFRα1 agonists have already
been developed.54,55 Such substances would not only simplify
the application procedure but would presumably also decrease
the chance of unwanted side effects that might result from
interaction with alternative GDNF receptors. If the Ret protein on
dopaminergic neurons is limiting, Retmight also be provided bya
viral vector approach targeting directly dopaminergic neurons.10
Such scenario has been created by high viral overexpression of
α-synuclein in rats leading to downregulation of the orphan
nuclear receptor Nurr-1 and its downstream target Ret.56
α-Synuclein is aggregating in Lewy bodies and neurites
frequently observed in PD patients and gene amplifications
and mutations of α-synuclein are found in some familiar forms of
PD.8,57 However, so far no58 or only mild56 reduction of Ret
mRNAand protein levels have been found in PD patients, so that
more investigations are needed to clarify this issue.
Taken together, our data support the ongoing clinical phase I
trials on PD patients testing AAV-encoded GDNF and phase II
trials using recombinant GDNF protein12 and emphasize the
central role of Ret in mediating GDNF’s survival and
regeneration signal in SNpc dopaminergic neurons under
neurodegenerative conditions that can cause PD.
It is likely that the beneficial effect of GDNF/Ret signaling
might be further enhanced andmore broadly applicable for the
heterogeneity of idiopathic PD patients if combined with other
neuroprotective and regenerative signals such as for example
parkin overexpression.29,53 Further experiments are needed
to support this hypothesis.
Materials and Methods
Recombinant vector production. Recombinant AAV5 viruses expressing
GDNF and EGFP were produced as described.34
Animal procedures. Transgenic mice were kept on a C57Bl/6J background
and were previously described.23,30 All experimental animal procedures were
conducted according to approved experimental animal licenses issued by the
responsible animal welfare authority (Niedersächsisches Landesamt für Verbrau-
cherschutz und Lebensmittelsicherheit) and controlled by the local animal welfare
committee of the University Medical Center Göttingen.
Figure 4 Quantification of striatal dopamine levels. Striatal dopamine levels assessed by HPLC are shown for control animals (NaCl), for animal receiving MPTP and AAV5-
EGFP (MPTP+EGFP), and for animals receiving MPTPand AAV5-GDNF (MPTP+GDNF) for the vector injected (inj) and the contralateral hemisphere (con). Data are shown from
the three genotypes (Dat-Cre, Retlx/lx mice and DAT-Retlx/lx) at 2 weeks (a) and at 3 months post MPTP treatment (b) (n= 6 animals per group)
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Unilateral stereotactical injection of 3 × 109 vector genomes (vg) of AAV5- GDNF or
AAV5-EGFP in 2–3-month-old male mice and MPTP treatment was done as
previously described.34 Animals were either sacrificed by cervical dislocation, the
striata dissected, frozen and stored at − 80 °C or animals were sacrificed using CO2
and after transcardial perfusion (10 min 0.1 M PBS, pH 7.4 and 10 min 4% PFA in
PBS) the whole brain was fixed and cryoprotected (24 h in 4% PFA and 48 h in 30%
sucrose at 4 °C).
Detection and quantification of GDNF. GDNF was quantified by IHC
staining and ELISA as described.34
Histology. Stereological counting of dopaminergic neurons was performed by the
optical fractionation method using StereoInvestigator as described.30 Glia cell and
dopaminergic fiber density quantification in the striatum was performed as described.23,30
Primary antibodies were used in the following concentrations: anti-TH (mouse,
1 : 2000, DiaSorin), anti-DAT (rat, 1 : 500, Millipore), anti-GFAP (rabbit, 1 : 300,
DacoCytomation), and anti-Iba-1 (rabbit, 1 : 500, Wako).
Quantification of dopamine, DOPAC and HVA. Catecholamine levels
were determined by ion-pair HPLC with electrochemical detection essentially as
described.30
Statistical analysis. Data are expressed as means±S.D. To compare
different group means for independent samples, the statistical analysis was
performed by ANOVA, followed by Tukey`s post hoc test (GraphPad Prism 4.0).
Significance levels were set at *Po0.05, **Po0.01 and ***Po0.001.
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